fda and compounded semaglutide issues warning about some versions of for diabetes, weight loss Compounded Semaglutide & Tirzepatide 2025:

Hormonal and blood-sugar disruption, including elevated cortisol and prolactin, reduced insulin sensitivity, and hypoglycemia risk tied to IGF-1 receptor activity

Current clinical guidance recommends restarting at the lowest dose when switching medications

Semaglutide and tirzepatide slow stomach emptying, which may delay absorption of oral medications or nutrients if taken too close together

They would also like to thank Catherine McBride at the University of Louisville for help with manuscript preparation, Dr

Several studies have shown that GLP-1 agonists can improve menstrual cyclicity, reduce hyperandrogenism, and increase ovulation rates in women with PCOS